Cardiovascular Institute, Allegheny General Hospital, 320 East North Ave, 16th floor, South Tower, Pittsburgh, PA, 15212, USA,
Curr Hypertens Rep. 2014 Dec;16(12):501. doi: 10.1007/s11906-014-0501-5.
Heart failure with preserved ejection fraction (HFpEF) is a major cause of HF-related morbidity and mortality, with no medical therapy proven to modify the underlying disease process and result in improvements in survival. With long-standing pulmonary venous congestion, a majority of HFpEF patients develop pulmonary hypertension (PH). Elevated pulmonary pressures have been shown to be a major determinant of mortality in this population. Given the paucity of available disease-modifying therapies for HFpEF, there has been a considerable interest in evaluating new therapeutic options specifically targeting PH in this patient population.
射血分数保留的心衰（HFpEF）是心衰相关发病率和死亡率的主要原因，目前尚无能够改变潜在疾病进程并改善生存率的医学治疗方法。由于长期存在肺静脉淤血，大多数 HFpEF 患者会发生肺动脉高压（PH）。研究表明，肺内高压是该人群死亡率的主要决定因素。鉴于 HFpEF 可用的疾病改善治疗方法有限，人们对评估专门针对该患者人群 PH 的新治疗选择产生了浓厚的兴趣。
